scispace - formally typeset
H

Hans-Peter Lenhof

Researcher at Saarland University

Publications -  170
Citations -  6982

Hans-Peter Lenhof is an academic researcher from Saarland University. The author has contributed to research in topics: Cancer & Macromolecular docking. The author has an hindex of 44, co-authored 164 publications receiving 6046 citations. Previous affiliations of Hans-Peter Lenhof include Max Planck Society.

Papers
More filters
Journal ArticleDOI

Novel immunogenic antigens increase classification accuracy in meningioma to 93.84

TL;DR: The results demonstrate that the accuracy of a serum‐based diagnostic can be readily and considerably improved by screening extended sets of proteins.
Journal ArticleDOI

RegulatorTrail: a web service for the identification of key transcriptional regulators.

TL;DR: RegulatorTrail is presented, a web service that provides rich functionality for the identification and prioritization of key transcriptional regulators that have a strong impact on natural and pathogenic processes, and successfully identified regulators that might explain the increased malignancy in metastatic melanoma compared to primary tumors, as well as important regulators in macrophages.
Proceedings ArticleDOI

ProteinScanAR - An Augmented Reality Web Application for High School Education in Biomolecular Life Sciences

TL;DR: This work presents ProteinScanAR, an augmented reality framework for biomolecular education that allows connecting virtual and real worlds intuitively, and thus enables focusing on the scientific or educational content.
Journal ArticleDOI

Integrated quantitative proteomic and transcriptomic analysis of lung tumor and control tissue: a lung cancer showcase

TL;DR: Principal Component Analysis provided evidence that not only cancer from control tissue but also tissue from adenocarcinoma and SCC can be differentiated.
Journal ArticleDOI

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.

TL;DR: A minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia is provided.